Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy

Molecular Cancer Therapeutics

Volumn 5, Issue 6, 2006, Pages 1577-1584

  Yoon, K Jin ^a   Qi, Jianjun ^b   Remack, Joanna S ^a   Virga, Kristopher G ^b   Hatfield, M Jason ^a   Potter, Philip M ^a   Lee, Richard E ^b   Danks, Mary K ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4' DIPIPERIDINE 1' CARBONYL CHLORIDE; 1,4' DIPIPERIDINE 1' CARBOXYLATE ETOPOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; ETOPOSIDE; ETOPOSIDE DERIVATIVE; IRINOTECAN; NEW DRUG; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RABBIT; STRUCTURE ANALYSIS;

ANIMALS; CAMPTOTHECIN; CARBOXYLESTERASE; CATALYSIS; CELL DIVISION; ETOPOSIDE; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; NEUROBLASTOMA; PRODRUGS; RABBITS; TUMOR CELLS, CULTURED;

EID: 33746056891     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0090     Document Type: Article

References (37)

1. Syrigos KN, Rowlinson-Busza G, Epenetos AA. In vitro cytotoxicity following specific activation of amygdalin by β-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Int J Cancer 1998;78:712-9.
2. Florent JC, Dong X, Gaudel G, et al. Prodrugs of anthracyclins for use in antibody-directed enzyme prodrug therapy. J Med Chem 1998;41:3572-81.
3. Syrigos KN, Epenetos AA. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Anticancer Res 1999;19:605-14.
4. Pawlik CA, Ivengar RV, Krull EJ, et al. Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11. Mol Ther 2000;May:457-63.
5. Meck MM, Wierdl M, Wagner LM, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11. Cancer Res 2001;61:5083-9.
6. Tychopoulos M, Corcos L, Genne P, Beaune P, de Waziers I. A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein. Cancer Gene Ther 2005;12:497-508.
7. Yoon KJ, Potter PM, Danks MK. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Curr Med Chem Anti-Canc Agents 2005;5:107-13.
8. Potter PM, Pawlik CA, Morton CL, Naeve CW, Danks MK. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998;58:2646-51.
9. Wagner LM, Guichard SM, Burger RA, et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002;62:5001-7.
10. Danks MK, Morton CL, Pawlik CA, Potter PM. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res 1998;58:20-2.
11. Schug KA, Linder W. Stereoselective discrimination and quantification of arginine and N-blocked arginine enantiomer by formation and dissociation of calcium-mediated diastereomeric trimer complexes with a chiral reference compound using electrospray ionization-ion trap tandem mass spectrometry. J Am Soc Mass Spectrom 2005;16:825-34.
12. Morton CL, Potter PM. Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression. Application to a rabbit liver carboxylesterase. Mol Biotechnol 2000;16:193-202.
13. Guichard SM, Morton CL, Krull EJ, Stewart CF, Danks MK, Potter PM. Conversion of the CPT-11 metabolite APC to SN-38 by rabbit liver carboxylesterase. Clin Cancer Res 1998;4:3089-94.
14. Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000;60:4725-8.
15. Danks MK, Morton CL, Krull EJ, et al. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 1999;5:917-24.
16. Jacobson LB, Calvin SA, Colvin KE, Wright M. FuGENE 6 transfection reagent: the gentle power. Methods 2004;33:104-12.
17. Yoon KJ, Hyatt JL, Morton CL, Lee RE, Potter PM, Danks MK. Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. Mol Cancer Ther 2004;3:903-9.
18. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
20. Chou TC, Talalay P. Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In: Harrap KR, Connors TA, editors. New Avenues in Developmental Cancer Chemotherapy Bristol Myers Symposium series. 1987. p. 37-64.
21. Chou TC, Rideout D, Chou J, Bertino JR. Chemotherapeutic synergism, potentiation and antagonism. In: Dulbecco R, editor. Encyclopedia of human biology. Vol. 2. Academic Press 1991. p. 371-9.
22. Henegar KE, Ashford SW, Baughman TA, Sih JC, Gu R-L. Practical asymmetric synthesis of (S)-4-ethyl-7,8-dihydro-1H-pyrano[3,4-f] indolizine-3,6,10(4H)-trion, a key intermediate for the synthesis of Irinotecan and other camptothecin analogs. J Org Chem 1997;62:6588-97.
23. Racha JK, Zhao ZS, Olejnik N, et al. Substrate dependent inhibition profile of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet 2003;18:128-38.
24. Bruzzese F, Di Gennaro F, Avallone A, et al. Synergistic antitumor activity epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2006;12:617-25.
25. Silva AT, Chung MC, Castro LF, Guido RV, Ferreira EI. Advances on prodrug design. Mini Rev Med Chem 2005;5:893-914.
26. Inagaki J, Yasui M, Sakata N, Inoue M, Yagi K, Kawa K. Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent. J Pediatr Hematol Oncol 2005;27:604-46.
27. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005;23:532-40.
28. Jikai J, Shamis M, Huebener N, et al. Neuroblastoma directed therapy by a rational prodrug design of etoposide as a substrate for tyrosine hydroxylase. Cancer Lett 2003;197:219-24.
29. Wrasidlo W, Schroder U, Bernt K, et al. Synthesis, hydrolytic activation and cytotoxicity of etoposide prodrugs. Bioorg Med Chem Lett 2002;12:557-60.
30. Lange B, Schroeder U, Huebener N, et al. Rationally designed hydrolytically activated etoposide prodrugs, a novel strategy for the treatment of neuroblastoma. Cancer Lett 2003;197:225-30.
31. Schmidt F, Monneret C. Prodrug mono therapy: synthesis and biological evaluation of etoposide glucuronide-prodrug. Bioorg Med Chem 2003;11:2277-83.
32. Yoon KJ, Krull EJ, Morton CL, et al. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Mol Cancer Ther 2003;2:1171-81.
33. Kudoh S, Nakamura S, Nakano T, et al. Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of west Japan thoracic oncology group. Lung Cancer 2005;49:263-9.
34. Houghton JA, Cheshire PJ, Hallman JD II, et al. Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. Clin Cancer Res 1996;2:107-18.
35. Barret JM, Etievant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated Vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol 2000;45:471-6.
36. Janss AJ, Cnaan A, Zhao H, et al. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs 1998;9:641-52.
37. Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 1996;88:734-41.